The chemotherapeutic management of advanced breast cancer is suboptimal, and results have plateaued in recent years. Investigation of new treatment approaches is warranted. Combined chemoendocrine therapy is one such approach, although results of this strategy to date have not been especially promising. The lack of an additive effect in some studies might be partially explained by an unfavorable interaction between the endocrine therapy and the cytotoxic therapy. Endocrine therapy slows breast cancer cell proliferation, and on a cell kinetic basis, may reduce chemosensitivity to certain drugs. In this proposal the mechanisms by which endocrine manipulation with estrogen withdrawal or with antiestrogens causes tumor regression will be studied using cultured human breast cancer cells, and cultured cell growing as subcutaneous tumors in athymic nude mice. Studies will be performed to determine whether endocrine therapy is lethal for breast cancer cells, or whether it simply slows their proliferation and induces an """"""""inactive"""""""" state. The importance of a functioning immune response to the tumor regression observed with hormone manipulation will be investigated, to test the hypothesis that inhibition of tumor cell proliferation coupled with an intact immune response are both required for maximal tumor regression with endocrine treatment. If inhibition of cell proliferation reduces chemosensitivity to certain drugs, then, perhaps, transient stimulation of the tumor with """"""""estrogen rescue"""""""" might result in an enhanced effect. The phenomenon of """"""""estrogen rescue,"""""""" which has been characterized in vitro in detail, will be studied in depth in vivo in the nude mouse tumor model. Binding to receptor, nuclear receptor processing, accumulation of mRNA, specific protein synthesis, and cell kinetic and growth alterations in response to estrogen replenishment of estrogen-deprived or antiestrogen-treated mice will be examined. When the timing of estrogen rescue has been defined, then the strategy of combined chemoendocrine therapy using estrogen rescue to stimulate the tumor in vivo will be studied to determine whether this technique can be exploited to increase chemosensitivity. These studies will provide important information on the antitumor mechanisms of hormone manipulation, and should lead to more rational therapeutic strategies using combined chemoendocrine therapy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
2R01CA030251-05
Application #
3169140
Study Section
Biochemical Endocrinology Study Section (BCE)
Project Start
1981-07-01
Project End
1987-12-31
Budget Start
1985-01-01
Budget End
1985-12-31
Support Year
5
Fiscal Year
1985
Total Cost
Indirect Cost
Name
University of Texas Health Science Center San Antonio
Department
Type
Schools of Medicine
DUNS #
800772162
City
San Antonio
State
TX
Country
United States
Zip Code
78229
Osborne, C K (1998) Tamoxifen in the treatment of breast cancer. N Engl J Med 339:1609-18
Nicholson, R I; Gee, J M; Bryant, S et al. (1996) Pure antiestrogens. The most important advance in the endocrine therapy of breast cancer since 1896. Ann N Y Acad Sci 784:325-35
Osborne, C K; Coronado-Heinsohn, E B; Hilsenbeck, S G et al. (1995) Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst 87:746-50
Osborne, C K; Jarman, M; McCague, R et al. (1994) The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth. Cancer Chemother Pharmacol 34:89-95
Koester, S K; Maenpaa, J U; Wiebe, V J et al. (1994) Flow cytometry: potential utility in monitoring drug effects in breast cancer. Breast Cancer Res Treat 32:57-65
Maenpaa, J; Wiebe, V; Wurz, G et al. (1994) Reduced tamoxifen accumulation is not associated with stimulated growth in tamoxifen resistance. Cancer Chemother Pharmacol 35:149-52
Maenpaa, J U; Wurz, G T; Baker, W J et al. (1993) A breast cancer clone selected by tamoxifen has increased growth rate and reduced sensitivity to doxorubicin. Oncol Res 5:461-6
Encarnacion, C A; Ciocca, D R; McGuire, W L et al. (1993) Measurement of steroid hormone receptors in breast cancer patients on tamoxifen. Breast Cancer Res Treat 26:237-46
Osborne, C K (1993) Mechanisms for tamoxifen resistance in breast cancer: possible role of tamoxifen metabolism. J Steroid Biochem Mol Biol 47:83-9
Wiebe, V J; Osborne, C K; Fuqua, S A et al. (1993) Tamoxifen resistance in breast cancer. Crit Rev Oncol Hematol 14:173-88

Showing the most recent 10 out of 33 publications